These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 25225241)

  • 1. History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fraction.
    Oluleye OW; Rector TS; Win S; McMurray JJ; Zile MR; Komajda M; McKelvie RS; Massie B; Carson PE; Anand IS
    Circ Heart Fail; 2014 Nov; 7(6):960-6. PubMed ID: 25225241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND.
    Brouwers FP; de Boer RA; van der Harst P; Voors AA; Gansevoort RT; Bakker SJ; Hillege HL; van Veldhuisen DJ; van Gilst WH
    Eur Heart J; 2013 May; 34(19):1424-31. PubMed ID: 23470495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ejection fraction and outcomes in patients with atrial fibrillation and heart failure: the Loire Valley Atrial Fibrillation Project.
    Banerjee A; Taillandier S; Olesen JB; Lane DA; Lallemand B; Lip GY; Fauchier L
    Eur J Heart Fail; 2012 Mar; 14(3):295-301. PubMed ID: 22294759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve).
    Böhm M; Perez AC; Jhund PS; Reil JC; Komajda M; Zile MR; McKelvie RS; Anand IS; Massie BM; Carson PE; McMurray JJ;
    Eur J Heart Fail; 2014 Jul; 16(7):778-87. PubMed ID: 24864045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of mortality and morbidity in patients with atrial fibrillation and heart failure with preserved versus decreased left ventricular ejection fraction.
    Badheka AO; Rathod A; Kizilbash MA; Bhardwaj A; Ali O; Afonso L; Jacob S
    Am J Cardiol; 2011 Nov; 108(9):1283-8. PubMed ID: 21855829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risks of Heart Failure, Stroke, and Bleeding in Atrial Fibrillation According to Heart Failure Phenotypes.
    Inciardi RM; Giugliano RP; Park JG; Nordio F; Ruff CT; Chen C; Lanz HJ; Antman EM; Braunwald E; Solomon SD
    JACC Clin Electrophysiol; 2023 Apr; 9(4):569-580. PubMed ID: 37100536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy.
    Krum H; Elsik M; Schneider HG; Ptaszynska A; Black M; Carson PE; Komajda M; Massie BM; McKelvie RS; McMurray JJ; Zile MR; Anand IS
    Circ Heart Fail; 2011 Sep; 4(5):561-8. PubMed ID: 21750125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and prognostic effects of atrial fibrillation in heart failure patients with reduced and preserved left ventricular ejection fraction.
    Linssen GC; Rienstra M; Jaarsma T; Voors AA; van Gelder IC; Hillege HL; van Veldhuisen DJ
    Eur J Heart Fail; 2011 Oct; 13(10):1111-20. PubMed ID: 21642293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial.
    Haass M; Kitzman DW; Anand IS; Miller A; Zile MR; Massie BM; Carson PE
    Circ Heart Fail; 2011 May; 4(3):324-31. PubMed ID: 21350053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of estimated plasma volume reduction on renal function for acute heart failure differs between patients with preserved and reduced ejection fraction.
    Takei M; Kohsaka S; Shiraishi Y; Goda A; Izumi Y; Yagawa M; Mizuno A; Sawano M; Inohara T; Kohno T; Fukuda K; Yoshikawa T;
    Circ Heart Fail; 2015 May; 8(3):527-32. PubMed ID: 25737498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of elevated heart rate on clinical outcomes in patients with heart failure with reduced and preserved ejection fraction: a report from the CHART-2 Study.
    Takada T; Sakata Y; Miyata S; Takahashi J; Nochioka K; Miura M; Tadaki S; Shimokawa H;
    Eur J Heart Fail; 2014 Mar; 16(3):309-16. PubMed ID: 24464774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.
    Cikes M; Claggett B; Shah AM; Desai AS; Lewis EF; Shah SJ; Anand IS; O'Meara E; Rouleau JL; Sweitzer NK; Fang JC; Saksena S; Pitt B; Pfeffer MA; Solomon SD
    JACC Heart Fail; 2018 Aug; 6(8):689-697. PubMed ID: 30007557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of atrial fibrillation in acute decompensated heart failure with reduced versus preserved ejection fraction.
    Jobs A; Schwind J; Katalinic A; Babaev V; Tilz RR; Rausch S; Thiele H; Eitel I; Eitel C
    Clin Res Cardiol; 2019 Jan; 108(1):74-82. PubMed ID: 29987595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atrial Fibrillation can adversely impact Heart Failure with Preserved Ejection Fraction by its association with Heart Failure Progression and Mortality: A Post-Hoc Propensity Score-Matched Analysis of the TOPCAT Americas Trial.
    Saksena S; Slee A; Natale A; Lakkireddy DR; Shah D; Di Biase L; Lewalter T; Nagarakanti R; Santangeli P
    Europace; 2023 May; 25(5):. PubMed ID: 37078691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial.
    Myhre PL; Vaduganathan M; Claggett BL; Anand IS; Sweitzer NK; Fang JC; O'Meara E; Shah SJ; Desai AS; Lewis EF; Rouleau J; Pitt B; Pfeffer MA; Solomon SD
    JAMA Cardiol; 2018 Oct; 3(10):1000-1005. PubMed ID: 30140899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Right ventricular dysfunction is a strong predictor of developing atrial fibrillation in acutely decompensated heart failure patients, ACAP-HF data analysis.
    Aziz EF; Kukin M; Javed F; Musat D; Nader A; Pratap B; Shah A; Enciso JS; Chaudhry FA; Herzog E
    J Card Fail; 2010 Oct; 16(10):827-34. PubMed ID: 20932465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between cardiovascular vs. non-cardiovascular co-morbidities and outcomes in heart failure with preserved ejection fraction.
    Lund LH; Donal E; Oger E; Hage C; Persson H; Haugen-Löfman I; Ennezat PV; Sportouch-Dukhan C; Drouet E; Daubert JC; Linde C;
    Eur J Heart Fail; 2014 Sep; 16(9):992-1001. PubMed ID: 25046483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential Prognostic Impact of Atrial Fibrillation in Hospitalized Heart Failure Patients With Preserved Ejection Fraction According to Coronary Artery Disease Status　- Report From the Japanese Nationwide Multicenter Registry.
    Temma T; Nagai T; Watanabe M; Kamada R; Takahashi Y; Hagiwara H; Koya T; Nakao M; Omote K; Kamiya K; Iwano H; Yamamoto K; Yoshikawa T; Saito Y; Anzai T
    Circ J; 2020 Feb; 84(3):397-403. PubMed ID: 32009066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs. worsening) and ejection fraction. Results from IN-HF Outcome Registry.
    Senni M; Gavazzi A; Oliva F; Mortara A; Urso R; Pozzoli M; Metra M; Lucci D; Gonzini L; Cirrincione V; Montagna L; Di Lenarda A; Maggioni AP; Tavazzi L;
    Int J Cardiol; 2014 May; 173(2):163-9. PubMed ID: 24630337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gender Differences in the Risk of Adverse Outcomes in Patients With Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction.
    O'Neal WT; Sandesara P; Hammadah M; Venkatesh S; Samman-Tahhan A; Kelli HM; Soliman EZ
    Am J Cardiol; 2017 Jun; 119(11):1785-1790. PubMed ID: 28395886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.